George Magrath: AI-native Biotechs Have Arrived

George Magrath, MD, CEO of Opus Genetics, joins Ram Yalamanchili to discuss how Opus is approaching portfolio-scale biotech development with multiple active clinical programs, something unimaginable without the use of AI. George believes the traditional single-asset biotech models may no longer be sustainable and that AI-native operations allow smaller teams to execute far more efficiently than ever before.With the rapid advancement of AI in discovery, clinical development has now become the biggest bottleneck in biotech. George also shares his perspective on rare disease development, operational scalability, and why the future of biotech is driven by the companies that have figured out AI-native clinical trial execution.